Search Results

spinning GPR68 small molecules into GIO New treatments being developed for schizophrenia Crinetics Pharmaceuticals

in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals

Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues

discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

amended deal with Gilead on anti-CCR8 antibody InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical

GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Industry News X4 Pharmaceuticals

immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics Pharmaceuticals

Research Associate NEW Research Technician Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals

| Chemotactic Cytokines GPCR Jobs NEW Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage X4 Pharmaceuticals

results for metabolic disorders INDIGO Biosciences, INC as a Preferred Supplier at Prendio Crinetics Pharmaceuticals

great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

biosensors involves the use of mini-G proteins, which are genetically engineered portions of Gα subunits designed Can the pharmaceutical industry reduce attrition rates? Innovation in the pharmaceutical industry: New estimates of R&D costs. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. Rational design of allosteric modulators: Challenges and successes.

great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

Months were spent debating assay design. IP1 isn’t naturally abundant or easy to detect. Eventually, the team landed on a design that could accumulate and detect IP1 in a 384-well format. But the moment we got bench-level data that aligned with our design—it became a breakthrough.” — Dr. David Parker spent years designing rare-earth europium probes. Trinquet’s team designed pHSense to detect that, without microscopy.

. ✅ Practical insight into how enzyme activation and inhibition shape drug safety, efficacy, and design The Overlooked Step in Every Discovery Program So what does that mean for discovery scientists designing You’re not just designing for receptor activity—you’re designing for enzyme survival. By mastering the difference, discovery teams can anticipate resistance, tune selectivity, and design Kenakin live for an open Q&A session designed for discovery scientists.

cryptic binding sites  and why some drugs need hours—not minutes—to equilibrate  ✅ A framework for designing Unexpected activity profiles, SAR that breaks your QSAR model, and missed opportunities to design more This has direct implications for: Assay timing and readout design Misclassification of lead candidates Design with Intelligence, Not Assumptions Whether you're aiming to discover PAMs, NAMs, or bias-selective modulators, the principles in this lecture equip you to design ligands that not only bind, but bind

New structural tools, AI-driven design pipelines, and a growing number of programs moving into the clinic programmes from discovery through translation — experts in GPCR biology, structural biology, computational design dig into this — moving beyond static potency and efficacy to mechanistic signatures that guide drug design primers on AI — they're teams presenting real workflows and real data, covering generative antibody design

cost-effective pharmacokinetic assays   Why Intracellular GPCR Drugs Change the Game For decades, drug design You get longer activity with shorter exposure—a dream scenario for drug designers. how this plays out in model systems and clinical data—and why residence time should be a first-class design He also reviews key scaffold properties that determine success, offering practical tips for design teams And while orthosteric ligands may never reach them, properly designed intracellular drugs can.

Effective PK optimization starts with realistic starting points Early property mapping accelerates the design–test–learn thinking and metabolic accounting  to proactively manage liabilities Clearance is not an endpoint—it is a design assays, protein binding, and permeability all carry confounders Data quality hinges on experimental design Continuous PK integration —from scaffold design through population modeling— correlates with clinical Designed for pharmacologists, medicinal chemists, and discovery leaders who refuse to rely on assumptions

Overcoming them requires careful assay design and strategic use of the right fluorescent probes. :  How HCS works and why it is increasingly central to GPCR-based drug discovery  The key phases of designing Assay Design and Pilot Optimization Successful HCS begins with a clearly defined biological question (A) After experimental design, wet lab work is performed to acquire high-content cell images, which then At Celtarys, we remain committed to enabling this transition and supporting researchers as they design

For drug discovery teams navigating safety margins, biased signaling, and combination therapy design, In this lesson, you’ll learn why this distinction is not just theory, but a practical framework to design This means you can design molecules that potentiate beneficial pathways without shutting down basal signaling The result is not just cleaner assay design but a sharper decision framework for selecting, prioritizing Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters

receptor theory with today’s most pressing pharmacological questions, from biased signaling to allosteric design Terry’s Corner gives you timeless and timely tools to improve selectivity, model efficacy, and design Upgrade Your Screening Strategy Leadership in Ligand Design  – The Celtarys Origin Story   In  this founder

Yet small design choices—often treated as technical details—quietly reshape the affinity you think you Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built reflects something deeper than metrics: a shared demand for clearer interpretation, stronger experimental design GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who

It would later shape how he designed fluorescent probes, how he evaluated biological constraints, and The project required designing peptide–fluorophore conjugates that would bind GLP-1R with high specificity Designing Reliable GPCR Imaging Tools for Real Biological Systems Success brought new challenges. This strategy accelerated discovery and reduced noise, helping them understand how each design change His team is exploring AI-enabled probe design, multiplex fluorescent strategies that allow visualization

By the end, you’ll know how to choose the right test, design experiments with power built in, and validate Once you learn to design with power analysis, you’ll never run blind again. Specifically, you’ll be able to: Design experiments with the right replicate count to balance rigor and It’s learning how to design, analyze, and decide with confidence built in. Terry’s Corner is designed to give you the edge.

Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent slowly fall apart is not confidence or optimism. ✅ It is the presence of someone actively designing Designing order also changes how teams experience pressure. Biotech does not become easy when an order is designed. It becomes survivable.   It is about designing clarity early enough that chaos never takes over.

present in the A 2A AR probe CELT-300 , new fluorescent ligands adapted to the NanoBRET® technology were designed The competitive assay design and optimization were performed in the University of Western Australia. The competitive assay design and optimization were performed in the University of Western Australia. For research teams, this provides a practical framework for integrating fluorescent ligand design with Design, Radiosynthesis, and Biodistribution of a New Potent and Selective Ligand for in Vivo Imaging

Myth of Multiple Affinity Sites Slows You Down Traditional models that shaped affinity analysis were designed Kenakin shows exactly how to separate what matters from what misleads—practical, real-world expertise designed Ingo Hartung : State-of-the-art design of small molecule drugs, including PROTACs Dr. His leadership principles: Hire for attitude and team fit—not just credentials Design workflows that GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions

Whether you’re early in your career or pushing the edge of MoA design, weekly lesson help you apply key Terry Kenakin   Terry’s Corner is your space focused on GPCR pharmacology designed just for you.   With strong signal stability, HTS compatibility, and broad assay versatility, CELT-419 is designed for